| Ytd | -8.99% | |
| 1y | 36.81% |
| Open | 19.03 | Prev Close | 19.31 | Low | 18.88 | High | 19.72 | Mkt Cap | 2.31B |
| Vol | 998.19K | Avg Vol | 1.20M | EPS | -2.55 | P/E | N/A | Forward P/E | -8.06 |
| Beta | 2.56 | Short Ratio | 15.70 | Inst. Own | 102.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 25.01 | 200-d Avg | 22.73 | 1yr Est | 35.20 |
IMNM News
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage tar
Stifel analyst Dara Azar initiates coverage on Immunome (NASDAQ:IMNM) with a Hold rating and anno
Immunome, Inc. (NASDAQ:IMNM), a clinical-stage targeted oncology company committed to developing fir
Alliance Global Partners analyst Matthew Venezia initiates coverage on Immunome (NASDAQ:IMNM) wit
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy
U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braz
Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raise
Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.65) per share which missed the analyst conse
U.S. stock futures mixed, Dow up 100 points. SpaceX stock falls 10.3% after reporting strong Q2 reve
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and mainta
FDA accepts Immunome's varegacestat NDA for desmoid tumors, with an April 28, 2027, PDUFA date b
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and bes
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and mainta
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and bes
Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raise
Barclays analyst Lukas Shumway initiates coverage on Immunome (NASDAQ:IMNM) with a Overweight rat
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.48) per share which beat the analyst consens
Immunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company dedicated to developing f
On Wednesday, 807 companies reached new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week
Gainers BEST Inc. (NYSE: BEST) shares gained 73.6% to close at $1.00. DiDi Global Inc. (NYSE: D
On Monday, 524 stocks hit new 52-week lows.
On Friday, 368 stocks hit new 52-week lows.
During Tuesday's trading, 505 companies set new 52-week lows.
During Wednesday's morning trading, 400 companies set new 52-week lows.
Tuesday morning saw 454 companies set new 52-week lows.
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) shares climbed 124.2% to settle at $3.99 on Thursday a
Gainers GameStop Corp. (NYSE: GME) shares surged 103.9% to close at $91.71 on Wednesday after the
Stocks That Hit 52-Week Highs On Friday Before 10 a.m. ET on Friday, 202 companies set new 52-we
This morning 533 companies reached new 52-week highs.
Before 10 a.m. ET on Wednesday, 192 companies set new 52-week highs.
On Tuesday morning, 172 companies achieved new highs for the year.
Gainers